BR112022012846A2 - Métodos de tratamento de condições relacionadas ao receptor s1p1 - Google Patents
Métodos de tratamento de condições relacionadas ao receptor s1p1Info
- Publication number
- BR112022012846A2 BR112022012846A2 BR112022012846A BR112022012846A BR112022012846A2 BR 112022012846 A2 BR112022012846 A2 BR 112022012846A2 BR 112022012846 A BR112022012846 A BR 112022012846A BR 112022012846 A BR112022012846 A BR 112022012846A BR 112022012846 A2 BR112022012846 A2 BR 112022012846A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- conditions related
- receiver
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Heat Treatment Of Sheet Steel (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957535P | 2020-01-06 | 2020-01-06 | |
| PCT/US2021/012367 WO2021142030A1 (en) | 2020-01-06 | 2021-01-06 | Methods of treating conditions related to the s1p1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012846A2 true BR112022012846A2 (pt) | 2022-09-06 |
Family
ID=76788331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012846A BR112022012846A2 (pt) | 2020-01-06 | 2021-01-06 | Métodos de tratamento de condições relacionadas ao receptor s1p1 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230338336A1 (https=) |
| EP (1) | EP4087562A4 (https=) |
| JP (1) | JP2023509698A (https=) |
| KR (1) | KR20220124209A (https=) |
| CN (1) | CN115066242A (https=) |
| AU (1) | AU2021205465A1 (https=) |
| BR (1) | BR112022012846A2 (https=) |
| CA (1) | CA3166828A1 (https=) |
| IL (1) | IL294071A (https=) |
| MX (1) | MX2022008342A (https=) |
| TW (1) | TW202135804A (https=) |
| WO (1) | WO2021142030A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4404930A1 (en) * | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| KR20240134360A (ko) * | 2022-01-13 | 2024-09-09 | 아레나 파마슈티칼스, 인크. | 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드 |
| CN118234492A (zh) * | 2022-10-21 | 2024-06-21 | 次代生物科学株式会社 | 具有针对s1pr1和s1pr4的功能性抑制剂作用的用于预防或治疗圆形脱发症的药物组合物 |
| KR102541577B1 (ko) * | 2022-10-21 | 2023-06-13 | 주식회사 넥스트젠바이오사이언스 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003061567A2 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| US8580841B2 (en) * | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| MX2012005560A (es) * | 2009-11-13 | 2012-10-05 | Receptos Inc | Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral. |
| ES2665461T3 (es) * | 2009-11-13 | 2018-04-25 | Celgene International Ii Sàrl | Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral |
| PH12012500940B1 (en) * | 2009-11-13 | 2018-09-26 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| US9198911B2 (en) * | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| PL3242666T3 (pl) * | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| MX2019009841A (es) * | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
-
2021
- 2021-01-06 AU AU2021205465A patent/AU2021205465A1/en not_active Abandoned
- 2021-01-06 US US17/790,632 patent/US20230338336A1/en not_active Abandoned
- 2021-01-06 TW TW110100496A patent/TW202135804A/zh unknown
- 2021-01-06 MX MX2022008342A patent/MX2022008342A/es unknown
- 2021-01-06 CA CA3166828A patent/CA3166828A1/en active Pending
- 2021-01-06 EP EP21738729.9A patent/EP4087562A4/en not_active Withdrawn
- 2021-01-06 BR BR112022012846A patent/BR112022012846A2/pt not_active IP Right Cessation
- 2021-01-06 JP JP2022541198A patent/JP2023509698A/ja active Pending
- 2021-01-06 CN CN202180013704.0A patent/CN115066242A/zh not_active Withdrawn
- 2021-01-06 KR KR1020227026729A patent/KR20220124209A/ko not_active Withdrawn
- 2021-01-06 IL IL294071A patent/IL294071A/en unknown
- 2021-01-06 WO PCT/US2021/012367 patent/WO2021142030A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220124209A (ko) | 2022-09-13 |
| CN115066242A (zh) | 2022-09-16 |
| CA3166828A1 (en) | 2021-07-15 |
| US20230338336A1 (en) | 2023-10-26 |
| MX2022008342A (es) | 2022-08-04 |
| EP4087562A1 (en) | 2022-11-16 |
| JP2023509698A (ja) | 2023-03-09 |
| TW202135804A (zh) | 2021-10-01 |
| EP4087562A4 (en) | 2024-01-10 |
| AU2021205465A1 (en) | 2022-07-14 |
| IL294071A (en) | 2022-08-01 |
| WO2021142030A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012846A2 (pt) | Métodos de tratamento de condições relacionadas ao receptor s1p1 | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| CY1118313T1 (el) | Παραγωγα καρβοστυρυλιου και σταθεροποιητες της διαθεσης για αντιμετωπιση διαταραχων της διαθεσης | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| MX2009002924A (es) | Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| AU2003256755A8 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| BR112021022216A2 (pt) | Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado | |
| BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
| MA58993A1 (fr) | Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| MA40769B1 (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA44612B1 (fr) | Méthodes de traitement de cancers pédiatriques | |
| BR112022007348A2 (pt) | Métodos para tratar condições relacionadas ao receptor s1p1 | |
| BRPI0406674B8 (pt) | composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| MX2023012455A (es) | Golexanolona para usarse en el tratamiento de la fatiga o deterioro cognitivo en pacientes con enfermedad hepatica. | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| MX2022011238A (es) | Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos. | |
| BR0312929A (pt) | Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo | |
| EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
| BR112022005999A2 (pt) | Métodos de tratamento de condições relacionadas ao receptor s1p1 | |
| MX2025007194A (es) | Antagonistas del receptor 1 del acido lisofosfatidico (lpa1) para el tratamiento de la enfermedad pulmonar intersticial | |
| BR112021024835A2 (pt) | Tratamento para sinuclenopatias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ARENA PHARMACEUTICALS, INC. (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 5A RETRIBUICAO ANUAL (VIDE PARECER). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2861 DE 04-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |